Treated for Inflammatory Bowel Diseases (IBD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Inflammatory Bowel Diseases (IBD)
Neuromodulation - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Early feasibility study of neuromodulation in patients with IBD.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: up to 3 years

up to 3 years
Disease Activity Index

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Treated
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Treated · No Placebo Group · N/A

Treated
Device
Experimental Group · 1 Intervention: Neuromodulation · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Neuromodulation
2011
Completed Phase 4
~30

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years

Who is running the clinical trial?

Boomerang MedicalLead Sponsor

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are aged 18 to 75 years.
You are able to comply with the protocol and are willing to comply with all follow-up requirements.
You have had the disease for at least 6 months.
You are able to understand and agree to participate in the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: November 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.